Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1850 of 8235 results

  1. Troriluzole for spinocerebellar ataxia [ID6456]

    Awaiting development Reference number: GID-TA11549 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. STS101 for treating acute migraine [TSID11782]

    Awaiting development Reference number: GID-TA11147 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development Reference number: GID-TA11507 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lenacapavir for treating multidrug resistant HIV-1 [ID6196]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. MT633 FreeO2 Automatic Oxygen Titration

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. MT656 Paige Prostate AI system for the detection of prostate cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. MT660 CerebAir for monitoring continuous, real-time EEG

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. MT658 Quit Genius for Smoking Cessation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. MT684 Smart Peak Flow for monitoring asthma

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. The Insides System chyme reinfusion system (MT682)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  16. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  17. Lumella Pre-Eclampsia point-of-care test for assessing pre-eclampsia risk (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  18. RespiraSense (MT736)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  19. Signatera molecular residual disease assay (MT741)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  20. Stockholm3 blood test for prostate cancer, (MT734),

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  21. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes, (MT740)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  22. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  23. Jada, (MT826)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  24. Urolon, (MT821)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  25. BPMpathway for rehabilitation support in joint replacement surgery, (MIB319)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  26. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  27. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  28. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  29. Electrosurgery (diathermy and coblation) for tonsillectomy, (IP324/2)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  30. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  31. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  32. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  33. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  40. Zoll ThermoGuard XP for Intravascular Temperature Management

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  41. Moor LDLS-BI for assessing burn depth and healing potential in children and adults

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  42. RenalSense Clarity RMS for acute kidney injury MT601 (MIB256)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  43. Syne Covid for predicting COVID-19 outcomes MT655

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  44. microINR for anticoagulation therapy MT592 (MIB257)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  45. Woundexpress MT602 (MIB261)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  46. Magtrace/Sentimag MT599 (MIB263)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  47. Acumen IQ sensor MT616 (MIB266)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  48. HealthVCF for detecting vertebral compression fractures on CT scans MT581 (MIB267)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  49. MMprofiler for prognostic risk classification in multiple myeloma (MT623) (MIB270)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  50. Colli-pee void urine collection device (MT628) (MIB273)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation